| A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo (NCT07647237) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2026-06-01 |
| A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma (NCT07452198) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2026-03-09 |
| A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers. (NCT07190716) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2025-10-10 |
| A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. (NCT07199257) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2025-09-25 |
| A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult (NCT07199270) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2025-09-18 |
| A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis (NCT07154342) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2025-08-15 |
| A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps (NCT06516302) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2024-09-19 |
| A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection (NCT06635798) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2024-09-03 |
| GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma (NCT06566547) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2024-08-26 |
| A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). (NCT06315426) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2024-03-24 |
| A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult (NCT06313697) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2024-03-23 |
| Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis (NCT06216392) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2024-01-01 |
| A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis. (NCT06175143) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2023-12-01 |
| The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps (NCT06015243) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2023-08-18 |
| The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers (NCT05954611) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2023-06-16 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults (NCT06302374) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2023-03-04 |
| The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps (NCT05873803) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2023-02-08 |
| Study to Evaluate GR1801's Efficacy and Safety (NCT05846568) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2022-10-21 |
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma (NCT06642961) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2022-07-19 |
| Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis (NCT05881785) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2022-06-13 |
| Phase I Trial of GR1803 Injection in Patients With RRMM (NCT07102706) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2022-05-27 |
| Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE (NCT06015230) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2022-03-08 |